FVB-Tg(KRT14-Vegfd)1Ali/Oulu

Status

Available to order

EMMA IDEM:09798
International strain nameFVB-Tg(KRT14-Vegfd)1Ali/Oulu
Alternative nameK14-mVEGF-D
Strain typeTransgenic Strains
Allele/Transgene symbolTg(KRT14-Vegfd)1Ali
Gene/Transgene symbolTg(KRT14-Vegfd)1Ali

Information from provider

ProviderKari Alitalo
Provider affiliationTranslational Cancer Biology Program, Wihuri Research Institute, University of Helsinki
Genetic informationTransgenic, murine Vegfd overexpression driven by keratin 14 promoter.
Phenotypic informationHomozygous:
Homozygous were not analyzed.

Heterozygous:
Hyperplastic lymphatic vasculature in the skin (Haiko et al. Mol Cell Biol. 2008 Aug;28(15):4843-50); changes in tumor inflammation and experimental skin tumor growth (Honkanen et al., 2016)
References
  • Deletion of vascular endothelial growth factor C (VEGF-C) and VEGF-D is not equivalent to VEGF receptor 3 deletion in mouse embryos.;Haiko Paula, Makinen Taija, Keskitalo Salla, Taipale Jussi, Karkkainen Marika J, Baldwin Megan E, Stacker Steven A, Achen Marc G, Alitalo Kari, ;2008;Molecular and cellular biology;28;4843-50; 18519586
  • Elevated VEGF-D Modulates Tumor Inflammation and Reduces the Growth of Carcinogen-Induced Skin Tumors.;Honkanen Hanne-Kaisa, Izzi Valerio, Petäistö Tiina, Holopainen Tanja, Harjunen Vanessa, Pihlajaniemi Taina, Alitalo Kari, Heljasvaara Ritva, ;2016;Neoplasia (New York, N.Y.);18;436-46; 27435926
Homozygous fertileyes
Homozygous viableyes
Homozygous matings requiredno
Immunocompromisedno

Information from EMMA

Archiving centreUniversity of Oulu, Oulu, Finland

Literature references

  • Deletion of vascular endothelial growth factor C (VEGF-C) and VEGF-D is not equivalent to VEGF receptor 3 deletion in mouse embryos.;Haiko Paula, Makinen Taija, Keskitalo Salla, Taipale Jussi, Karkkainen Marika J, Baldwin Megan E, Stacker Steven A, Achen Marc G, Alitalo Kari, ;2008;Molecular and cellular biology;28;4843-50; 18519586
  • Elevated VEGF-D Modulates Tumor Inflammation and Reduces the Growth of Carcinogen-Induced Skin Tumors.;Honkanen Hanne-Kaisa, Izzi Valerio, Petäistö Tiina, Holopainen Tanja, Harjunen Vanessa, Pihlajaniemi Taina, Alitalo Kari, Heljasvaara Ritva, ;2016;Neoplasia (New York, N.Y.);18;436-46; 27435926

Information on how we integrate external resources can be found here

Order

Availabilities

Requesting frozen sperm or embryos is generally advisable wherever possible, in order to minimise the shipment of live mice.

  • Frozen embryos. Delivered in 4 weeks (after paperwork in place). €1740*
  • Frozen sperm. Delivered in 4 weeks (after paperwork in place). €1740*
  • Rederivation of mice from frozen stock, delivery time available upon request . €3880*

Due to the dynamic nature of our processes strain availability may change at short notice. The local repository manager will advise you in these circumstances.

* In addition users have to cover all the shipping costs (including the cost for returning dry-shippers, where applicable).

More details on pricing and delivery times

Practical information

Genotyping protocol

Example health report
(Current health report will be provided later)

Material Transfer Agreement (MTA)
For this strain no provider MTA is needed. Distribution is based on the EMMA conditions only.

EMMA conditions
Legally binding conditions for the transfer

Other EMMA strains

Not found what you were looking for? Search here for other strains available from EMMA.


Search
INFRAFRONTIER® and European Mouse Mutant Archive - EMMA® are registered trademarks at the European Union Intellectual Property Office (EUIPO).